TPH1 and hyperlipidemia: In this regard, a study with HFD-induced diabetes in mice has already shown that oral administration of the TPH1 inhibitor LP533401 led to an improvement of peripheral insulin sensitivity and glucose tolerance as well as a reduction of hyperglycemia and hyperlipidemia [27].